News | Atrial Fibrillation | September 24, 2015

ACC Launches Two Afib-Related Registry Programs

Registries to track ablation and left atrial appendage occlusion procedures

ACC, atrial fibrillation registries, ablation, left atrial appendage occlusion procedures, LAAO Registry

September 24, 2015 — The American College of Cardiology (ACC) launched two new clinical registry programs in August to track real-world outcomes for the treatment and stroke prevention of patients with atrial fibrillation.

“With a growing prevalence of atrial fibrillation and growing options for treatment and stroke prevention in afib patients, the ACC saw a need for real-world data to track and evaluate the use of these new technologies,” said ACC President Kim A. Williams Sr., M.D., FACC. “Data derived from these registries are expected to inform practices and improve patient outcomes.”

In coming months, the ACC will launch the LAAO Registry, which will capture data on left atrial appendage occlusion procedures to assess real-world procedural indications and outcomes, as well as short- and long-term safety. Left atrial appendage occlusion procedures provide a treatment option to manage stroke risk for non-valvular atrial fibrillation patients who are unable to maintain adequate anticoagulation through medication therapy.

The college is also planning the AFib Ablation Registry to assess the prevalence, demographics, acute management and outcomes of patients undergoing atrial fibrillation ablation procedures. Its data will support the development of evidence-based guidelines and quality metrics for atrial fibrillation treatments that will improve outcomes for afib patients.

These two new clinical registry programs join eight other programs that comprise the National Cardiovascular Data Registry, the ACC’s suite of cardiovascular data registries that help hospitals and clinical practices measure and improve the quality of care they provide. 

For more information: www.acc.org


Related Content

News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
News | EP Lab

April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...

Home April 21, 2025
Home
News | EP Lab

Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home February 14, 2025
Home
News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...

Home June 25, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
News | EP Lab

January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...

Home January 11, 2024
Home
Subscribe Now